日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination

BNT162b3疫苗接种后,小鼠和恒河猴体内针对SARS-CoV-2病毒产生了强烈且早期的免疫反应。

Vogel, Annette B; Lui, Bonny G; Tompkins, Kristin; Kanevsky, Isis; Muik, Alexander; Krumm, Stefanie A; Güler, Alptekin; Maddur, Mohan S; Walzer, Kerstin C; Witzel, Sonja; Vascotto, Fulvia; Stanganello, Eliana; Ota-Setlik, Ayuko; Cottingham, Kimberly J; Allbritton, Omaira; Keverne, Jessica; Aragão-Santiago, Letícia; Swanson, Kena A; Türeci, Özlem; Şahin, Uğur

Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines

BNT162b2 JN.1 和 KP.2 改良型 COVID-19 疫苗的免疫学和生物物理学特征

Chen, Wei; Tompkins, Kristin R; Windsor, Ian W; Martinez, Lyndsey T; Ramos, Minah; Li, Weiqiang; Shrivastava, Shikha; Rajput, Swati; Chang, Jeanne S; Sahasrabudhe, Parag; Fennell, Kimberly F; McLellan, Thomas J; West, Graham M; Dizon, Kristianne P; Yam, Aaron; Mitra, Siddartha; Saha, Subrata; Sharaf, Daiana; McKeen, Andrew P; Cadima, Carla I; Muik, Alexander; Swanson, Wesley; Munoz Moreno, Raquel; Mendoza Daroca, Pilar; Sahin, Ugur; Anderson, Annaliesa S; Wu, Huixian; Swanson, Kena A; Modjarrad, Kayvon

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects

Acasunlimab 是一种 Fc 惰性 PD-L1×4-1BB 双特异性抗体,与 PD-1 阻断剂联合使用可通过互补的免疫调节作用增强抗肿瘤免疫力。

Michela Capello # ,Angelica Sette # ,Theo Plantinga ,Craig J Thalhauser ,Vanessa M Spires ,Kristina B Nürmberger ,Jordan M Blum ,Brandon W Higgs ,Patricia Garrido Castro ,Christina Yu ,Carol Costa Sa ,Sina Fellermeier-Kopf ,Saskia M Burm ,Kristin Strumane ,Aras Toker ,Andrea Imle ,Bruna de Andrade Pereira ,Alexander Muik ,Tahamtan Ahmadi ,Özlem Türeci ,Mark Fereshteh ,Ugur Sahin ,Maria Jure-Kunkel ,Nora Pencheva

Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

利用临床前和临床数据,采用 mPBPK/RO 模型选择 DuoBody®-CD40x4-1BB (GEN1042/BNT312) 的剂量

Bajaj, Gaurav; Shchelokov, Dmitry; Demin, Oleg Jr; Adams, Homer C 3rd; Feng, Yan; Gibiansky, Leonid; van der Lee, Saskia; Johri, Anandhi; Belete, Merzu; Muik, Alexander; Panorchan, Porntula; Türeci, Özlem; Sahin, Uğur; Ahmadi, Tahamtan; Gupta, Manish; Demin, Oleg; Thalhauser, Craig

A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade

一种经六聚化增强、Fc沉默的激动性CD27抗体,可作为单药或与PD-1阻断剂联合使用,增强T细胞效应功能。

Işıl Altıntaş ,Kristina B Nürmberger ,Andrea Imle ,Anna-Lena Krause ,Marike M van Beuge ,Aras Toker ,Andreea Ioan-Facsinay ,Jordan Blum ,Alexander Muik ,Frank J Beurskens ,Rob N de Jong ,David P E Satijn ,Friederike Gieseke ,Bart-Jan de Kreuk ,Maarten van der Kroef ,Sina Fellermeier-Kopf ,Tahamtan Ahmadi ,Özlem Türeci ,Esther C W Breij ,Uğur Şahin

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

COVID-19 疫苗 BNT162b1 可引发人类抗体和 TH1 T 细胞反应

Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M Kranz, Mathias Vormehr, Alina Baum, Kristen Pascal, Jasmin Quandt, Daniel Maurus, Sebastian Brachtendorf, Verena Lörks, Julian Sikorski, Rolf Hilker, Dirk Becker, Ann-Kathrin Eller, Jan Grützner, Carsten Boesler, Corinna Rosen

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.

Omicron XBB.1.5 适应性 BNT162b2 COVID-19 疫苗的临床前表征

Modjarrad Kayvon, Che Ye, Chen Wei, Wu Huixian, Cadima Carla I, Muik Alexander, Maddur Mohan S, Tompkins Kristin R, Martinez Lyndsey T, Cai Hui, Ramos Minah, Mensah Sonia, Cumbia Brittney, Falcao Larissa, McKeen Andrew P, Chang Jeanne S, Fennell Kimberly F, Huynh Kevin W, McLellan Thomas J, Sahasrabudhe Parag V, Chen Wei, Cerswell Michael, Garcia Miguel A, Li Shilong, Sharma Rahul, Li Weiqiang, Dizon Kristianne P, Duarte Stacy, Gillett Frank, Smith Rachel, Illenberger Deanne M, Efferen Kari Sweeney, Vogel Annette B, Anderson Annaliesa S, Şahin Uğur, Swanson Kena A

Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

二价疫苗对BA.4-BA.5、BA.4.6、BA.2.75.2、BQ.1.1和XBB.1的中和作用

Zou, Jing; Kurhade, Chaitanya; Patel, Sohil; Kitchin, Nicholas; Tompkins, Kristin; Cutler, Mark; Cooper, David; Yang, Qi; Cai, Hui; Muik, Alexander; Zhang, Ying; Lee, Dung-Yang; Şahin, Ugur; Anderson, Annaliesa S; Gruber, William C; Xie, Xuping; Swanson, Kena A; Shi, Pei-Yong

Early computational detection of potential high-risk SARS-CoV-2 variants

早期计算检测潜在的高风险 SARS-CoV-2 变体

Karim Beguir, Marcin J Skwark, Yunguan Fu, Thomas Pierrot, Nicolas Lopez Carranza, Alexandre Laterre, Ibtissem Kadri, Abir Korched, Anna U Lowegard, Bonny Gaby Lui, Bianca Sänger, Yunpeng Liu, Asaf Poran, Alexander Muik, Uğur Şahin

SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

SARS-CoV-2 Omicron 变异株:疾病负担、对疫苗有效性的影响以及对变异株适应性疫苗的需求

Pather, Shanti; Madhi, Shabir A; Cowling, Benjamin J; Moss, Paul; Kamil, Jeremy P; Ciesek, Sandra; Muik, Alexander; Türeci, Özlem